• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dexcom Reveals Global Diabetes Advocates: New Voices for Diabetes Awareness This World Diabetes Day

    11/14/25 8:00:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care
    Get the next $DXCM alert in real time by email
    • Sourced from the diabetes community at large through an open call earlier this year, the 16 selected advocates represent strength, advocacy and pride in living with Type 1, Type 2 and prediabetes
    • Dexcom's World Diabetes Day campaign provides a platform for the selected individuals to advocate for diabetes awareness through their unique, personal stories on a global stage

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today unveiled 16 new diabetes advocates to represent people living with diabetes globally as part of Dexcom's World Diabetes Day campaign.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114585651/en/

    Dexcom's World Diabetes Day campaign provides a platform for the selected individuals to advocate for diabetes awareness through their unique, personal stories on a global stage.

    Dexcom's World Diabetes Day campaign provides a platform for the selected individuals to advocate for diabetes awareness through their unique, personal stories on a global stage.

    The advocates – ranging from ages six to 68, spanning various types of diabetes, and hailing from four continents and five countries – were selected from 1,000 open call submissions based on their experiences advocating for people with diabetes in their communities. While each person's experience with diabetes is unique, they share a common passion for advocacy – and use of Dexcom's glucose biosensing technology.

    "Through advocacy, I strive to show others, especially children and newly diagnosed patients, that diabetes is not a limitation but an opportunity to grow stronger, inspire resilience and pursue ambitious goals," said Maria Alejandra Jove Valerio, one of Dexcom's new advocates. "What began as a diagnosis at age seven has grown into a lifelong mission to uplift others."

    This effort represents the first time Dexcom has sourced voices from the broader diabetes community specifically for its World Diabetes Day campaign, reinforcing Dexcom's history of and commitment to giving real people with diabetes a platform to share their story on a global stage.

    Through engaging, editorial-style portraits and deeply personal stories, the campaign highlights each advocate's personal experience with diabetes, what misconceptions about diabetes they'd like to dispel and how they want to inspire others with diabetes to discover what they're made of.

    To prepare for the spotlight, the group of advocates met in Los Angeles for a World Diabetes Day photoshoot which included a surprise visit from Grammy-nominated artist, actor, producer and Dexcom Warrior Lance Bass and author, producer, actress and Stelo* Ambassador Retta. This visit offered the advocates an opportunity to exchange stories and personal perspectives on the meaning of diabetes advocacy and how they live it each day.

    Behind the lens at the shoot was another member of the diabetes community—photographer Tommy Lundberg who lives with Type 1 diabetes.

    "Directing this photoshoot was nothing short of inspiring. Each of these advocates has a unique and compelling story, but they are all bonded by the shared experience of living with diabetes and passion for helping others in their diabetes journey," said Lundberg. "I'm looking forward to people around the world seeing the strength of their advocacy shine through in this meaningful campaign."

    Meet the New Dexcom Diabetes Advocates:

    • Ben Schwinof: Portland, OR, United States | Age 50, Type 2 Diabetes
    • Bridget Curran: New York, NY, United States | Age 56, Prediabetes
    • Bruce Moss: Durango, CO, United States | Age 67, Type 1 Diabetes
    • Cindy Reinl: Stuttgart, Germany | Age 26, Type 1 Diabetes
    • Darrell Byers: Boston, United States | Age 64, Type 2 Diabetes
    • Isabelle da Silva: Boca Raton, FL, United States | Age 6, Type 1 Diabetes
    • Jacob Cain: Mesa, AZ, United States | Age 49, Type 2 Diabetes
    • Kari Cichoski: Las Vegas, NV, United States | Age 38, Type 1 Diabetes
    • Kate Beaulieu: Toronto, ON, Canada | Age 20, Type 1 Diabetes
    • Kaye Peterson: Lebanon, KY, United States | Age 68, Type 1 Diabetes
    • Lachie Kennedy: Brisbane, Australia | Age 22, Type 1 Diabetes
    • Maria Alejandra Jove Valerio: Boston, MA, United States | Age 20, Type 1 Diabetes
    • MiYeong Kim: Seoul, South Korea | Age 48, Mother to a Son with Type 1 Diabetes
    • Sofia Pansini: Boston, MA, United States | Age 21, Type 1 Diabetes
    • Tajah Russell: Dallas, TX, United States | Age 31, Type 1 Diabetes
    • Tai'yon Allen Walker: Annapolis, MD, United States | Age 11, Type 1 Diabetes

    To learn more about the advocates' stories, visit Dexcom.com/WorldDiabetesDay or follow Dexcom on Facebook, Instagram or TikTok.

    About Dexcom

    Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

    Dexcom. Discover what you're made of. For more information, visit www.dexcom.com.

    *Stelo is cleared by the FDA for adults not on insulin who are 18 older in the United States.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251114585651/en/

    Media Contact

    Nadia Conard

    [email protected]

    Investor Contact

    Sean Christensen

    [email protected]

    Get the next $DXCM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DXCM

    DatePrice TargetRatingAnalyst
    10/21/2025$85.00Buy
    Stifel
    9/8/2025Outperform → Perform
    Oppenheimer
    8/21/2025$100.00Buy
    Argus
    6/16/2025$102.00Buy
    Truist
    5/30/2025$104.00Buy
    Goldman
    4/10/2025$85.00Outperform
    Mizuho
    2/3/2025$85.00 → $115.00Neutral → Buy
    Redburn Atlantic
    1/16/2025$86.00 → $104.00Neutral → Outperform
    Robert W. Baird
    More analyst ratings

    $DXCM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & COO Leach Jacob Steven bought $1,001,702 worth of shares (18,200 units at $55.04), increasing direct ownership by 6% to 331,697 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    11/10/25 7:13:08 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dexcom Reveals Global Diabetes Advocates: New Voices for Diabetes Awareness This World Diabetes Day

    Sourced from the diabetes community at large through an open call earlier this year, the 16 selected advocates represent strength, advocacy and pride in living with Type 1, Type 2 and prediabetes Dexcom's World Diabetes Day campaign provides a platform for the selected individuals to advocate for diabetes awareness through their unique, personal stories on a global stage DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today unveiled 16 new diabetes advocates to represent people living with diabetes globally as part of Dexcom's World Diabetes Day campaign. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2

    11/14/25 8:00:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Québec Expands Access to Dexcom CGM under the Régie de l'assurance maladie du Québec (RAMQ)

    New RAMQ coverage means eligible Québec residents with type 2 diabetes on intensive insulin therapy can now access Dexcom Continuous Glucose Monitoring (CGM) to simplify diabetes management. Dexcom, Inc. (NASDAQ:DXCM), a global leader in glucose biosensing, applauds the Québec government for its recent decision to expand coverage of Dexcom Continuous Glucose Monitoring (CGM) Systems under the Régie de l'assurance maladie du Québec (RAMQ) for eligible Québecers aged 18 and older living with type 2 diabetes who are treated with intensive insulin therapy (IIT)*. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106123887/en/Quebec

    11/6/25 8:34:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Guidance

    DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights: Revenue grew 22% year-over-year to $1.209 billion on a reported basis and 20% year-over-year on an organic1 basis. U.S. revenue grew 21% and international revenue grew 22% on a reported basis and 18% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $242.5 million or 20.1% of revenue, an increase of 480 basis points compared to the third quarter of 2024. Non-GAAP operating income* of $272.9 million or 22.6% of reported revenue, an increase of 130 basis points compared to the third quarter of 2024.

    10/30/25 4:02:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Heller Bridgette P sold $58,767 worth of shares (1,012 units at $58.07), decreasing direct ownership by 4% to 27,031 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    11/12/25 5:14:37 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    President & COO Leach Jacob Steven bought $1,001,702 worth of shares (18,200 units at $55.04), increasing direct ownership by 6% to 331,697 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    11/10/25 7:13:08 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Director Collins Richard Alexander sold $217,811 worth of shares (3,948 units at $55.17) (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    11/10/25 7:12:40 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    SEC Filings

    View All

    SEC Form 144 filed by DexCom Inc.

    144 - DEXCOM INC (0001093557) (Subject)

    11/12/25 10:52:52 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by DexCom Inc.

    144 - DEXCOM INC (0001093557) (Subject)

    11/10/25 9:52:13 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by DexCom Inc.

    10-Q - DEXCOM INC (0001093557) (Filer)

    10/30/25 5:19:54 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel resumed coverage on Dexcom with a new price target

    Stifel resumed coverage of Dexcom with a rating of Buy and set a new price target of $85.00

    10/21/25 7:19:41 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom downgraded by Oppenheimer

    Oppenheimer downgraded Dexcom from Outperform to Perform

    9/8/25 8:40:02 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Argus initiated coverage on Dexcom with a new price target

    Argus initiated coverage of Dexcom with a rating of Buy and set a new price target of $100.00

    8/21/25 8:05:28 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Leadership Updates

    Live Leadership Updates

    View All

    Dexcom Appoints Euan Ashley to Board of Directors

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Euan Ashley to its Board of Directors, effective October 24, 2025. Dr. Ashley is a renowned researcher, entrepreneur, and clinician with extensive leadership experience at healthcare research institutions and private organizations. He currently serves as Chair of the Department of Medicine at Stanford University, overseeing Stanford's largest department with 15 divisions and over 800 faculty. Dr. Ashley's research extends across precision medicine, data science, artificial intelligence, and digital health. He has also co-founded seven biotechnology companies and serves as the co-directo

    10/27/25 4:15:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Synchron Expands Executive Team with Appointment of Andy Rasdal as Chief of Staff and Mark Brister as VP R&D

    Medical device leaders who have built and scaled category-defining products join Synchron to help drive its next-generation brain-computer interface platform as well as accelerate towards commercialization Synchron, a category-defining brain-computer interface (BCI) company, today announced the appointment of Andy Rasdal as Chief of Staff and Mark Brister as VP R&D. The appointments bring deep experience in launching and scaling category-leading medical devices, positioning Synchron to advance its Stentrode® BCI through U.S. clinical trials and prepare for global market entry. Mr. Rasdal, who joined Synchron's Board of Directors in 2023, will transition into a full-time executive role

    8/19/25 8:00:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews

    Dexcom's first-of-its-kind NIL program welcomes 13 new athletes and eight returning team members, including San Diego State University basketball standout Miles Byrd and Alabama A&M University's Shelomi Sanders The trailblazing program empowers college athletes with Type 1 diabetes to break barriers in sports and inspire their communities, as showcased at the Dexcom U Signing Day Camp, a new addition to the program, earlier this month DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the launch of the fourth season of Dexcom U, the company's one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes. This pr

    7/17/25 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Financials

    Live finance-specific insights

    View All

    Dexcom Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Guidance

    DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights: Revenue grew 22% year-over-year to $1.209 billion on a reported basis and 20% year-over-year on an organic1 basis. U.S. revenue grew 21% and international revenue grew 22% on a reported basis and 18% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $242.5 million or 20.1% of revenue, an increase of 480 basis points compared to the third quarter of 2024. Non-GAAP operating income* of $272.9 million or 22.6% of reported revenue, an increase of 130 basis points compared to the third quarter of 2024.

    10/30/25 4:02:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Schedules Third Quarter 2025 Earnings Release and Conference Call for October 30, 2025 at 4:30 p.m. Eastern Time.

    DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2025 financial results after market close on Thursday, October 30, 2025. Management will hold a conference call to review the company's third quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the

    10/2/25 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Reports Second Quarter 2025 Financial Results, Updates Full Year 2025 Guidance and Announces CEO Succession Plan

    DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights: Revenue grew 15% year-over-year to $1.157 billion on a reported basis and 15% year-over-year on an organic1 basis. U.S. revenue grew 15% and international revenue grew 16% on a reported basis and 14% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $212.6 million or 18.4% of revenue, an increase of 270 basis points compared to the second quarter of 2024. Non-GAAP operating income* of $221.8 million or 19.2% of reported revenue, a decrease of 30 basis points compared to the second quarter of 2024. S

    7/30/25 4:02:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/13/24 5:02:33 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/9/23 11:16:37 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/9/22 3:43:37 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care